The translational challenges in the field of precision oncology are in part related to the biological complexity and diversity of this disease. Technological advances in genomics …
Identification of cancer driver mutations that confer a proliferative advantage is central to understanding cancer; however, searches have often been limited to protein-coding …
F Dietlein, AB Wang, C Fagre, A Tang, NJM Besselink… - Science, 2022 - science.org
We established a genome-wide compendium of somatic mutation events in 3949 whole cancer genomes representing 19 tumor types. Protein-coding events captured well …
Mutations in human proteins lead to diseases. The structure of these proteins can help understand the mechanism of such diseases and develop therapeutics against them. With …
L Cheng, S Zhang, M Wang, A Lopez-Beltran - Human Pathology, 2022 - Elsevier
The telomerase reverse transcriptase (TERT) promoter mutations are associated with increased TERT mRNA and TERT protein levels, telomerase activity, and shorter but stable …
HI Suzuki, K Onimaru - Cancer Science, 2022 - ncbi.nlm.nih.gov
Understanding the characteristics of cancer cells is essential for the development of improved diagnosis and therapeutics. From a gene regulation perspective, the super …
S Sargazi, ER Simge, SS Gelen, A Rahdar… - Journal of Drug Delivery …, 2022 - Elsevier
The usage of nanoparticles (NPs) in treating and diagnosing many diseases, especially cancer, has been investigated in recent studies. The primary purpose of using …
M Boström, E Larsson - Nature communications, 2022 - nature.com
Cancer gene discovery is reliant on distinguishing driver mutations from a multitude of passenger mutations in tumour genomes. While driver genes may be revealed based on …
The characterization of immortalized canine osteosarcoma (OS) cell lines used for research has historically been based on phenotypic features such as cellular morphology and …